Abstract
Elacestrant (ORSERDU (TM)) is an orally available selective estrogen receptor degrader (SERD) being developed by Stemline Therapeutics, a subsidiary o......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
